| Nuplazid (pimavanserin) / Acadia Pharma |
2016-003437-18: A phase 3 study to Evaluate the Efficacy and Safety of Pimavanserin for the Treatment of Schizophrenia |
|
|
| Ongoing | 3 | 308 | Europe | Pimavanserin, ACP-103, Tablet | ACADIA Pharmaceuticals Inc., ACADIA Pharmaceuticals Inc. | Schizophrenia, Chronic, debilitating mental illness characterized by disturbances in thinking, emotional reaction, and behavior, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2018-003251-37: A study to evaluate the safety of Pimavanserin therapy in subject with Major Depressive Disorder |
|
|
| Not yet recruiting | 3 | 280 | Europe | Pimavanserin, ACP-103, Film-coated tablet | ACADIA Pharmaceuticals Inc, ACADIA Pharmaceuticals Inc | Major Depressive Disorder, Major Depressive Disorder, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2018-003252-20: A study of the safety of pimavanserin in adult subjects with major depressive disorder |
|
|
| Not yet recruiting | 3 | 420 | Europe | Pimavanserin, ACP-103, Film-coated tablet | ACADIA Pharmaceuticals Inc, Acadia Pharmaceuticals Inc, ACADIA Pharmaceuticals Inc, Acadia Pharmaceuticals Inc | Major Depressive Disorder, Major Depressive Disorder, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2016-003512-12: A safety and tolerability study of Pimavanserin in patients with Parkinson's Disease Psychosis |
|
|
| Not yet recruiting | 3 | 8 | Europe | Pimavanserin, pimavanserin (ACP-103), Film-coated tablet | ACADIA Pharmaceuticals Inc., ACADIA Pharmaceuticals Inc. | Psychosis in Parkinson's Disease, Diseases [C] - Nervous System Diseases [C10] | | | | |
NCT03623321 / 2017-004439-36: Extension Study of Pimavanserin in Adult Subjects With Neuropsychiatric Symptoms Related to Neurodegenerative Disease |
|
|
| Completed | 3 | 595 | Europe, US, RoW | Pimavanserin | ACADIA Pharmaceuticals Inc. | Neuropsychiatric Symptoms Related to Neurodegenerative Disease | 05/23 | 05/23 | | |
| Active, not recruiting | 3 | 454 | Europe, RoW | Pimavanserin, Placebo | ACADIA Pharmaceuticals Inc. | Schizophrenia | 01/24 | 01/24 | | |
|
|
| Terminated | 3 | 996 | Europe, Canada, US, RoW | Pimavanserin | ACADIA Pharmaceuticals Inc. | Schizophrenia | 06/24 | 06/24 | | |
| Recruiting | 3 | 248 | RoW | pimavanserin tartrate, placebo | Tasly Pharmaceutical Group Co., Ltd | Parkinson's Disease Psychosis | 06/25 | 01/26 | | |
| Active, not recruiting | 2/3 | 228 | Europe, US, RoW | Pimavanserin, Nuplazid, Placebo | ACADIA Pharmaceuticals Inc. | Irritability Associated With Autism Spectrum Disorder | 09/24 | 09/24 | | |
| Recruiting | 2/3 | 228 | Europe, US, RoW | Pimavanserin, Nuplazid | ACADIA Pharmaceuticals Inc. | Irritability Associated With Autism Spectrum Disorder | 07/25 | 07/25 | | |
